L-methadone and D,L-methadone in methadone maintenance treatment: A comparison of therapeutic effectiveness and plasma concentrations

European Addiction Research

Volumn 4, Issue 3, 1998, Pages 134-141

  De Vos, Jan W ^a,e   Ufkes, Jan G R ^a   Kaplan, Charles D ^b   Tursch, Marcus ^c   Krause, Joachim K A ^c   Van Wilgenburg, Henk ^a   Woodcock, Barry G ^d   Horst Staib, A ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Substitutionsambulanz M ^*

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e HG   (Netherlands)

Author keywords

Craving; Experience sampling method; Heroin dependence; HPLC; L methadone; Methadone; Methadone maintenance treatment; Stereoisomers

Indexed keywords

LEVOMETHADONE; METHADONE; OPIATE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN CELL; MALE; METHADONE TREATMENT; OBSERVATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WITHDRAWAL SYNDROME;

ADULT; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; ISOMERISM; MALE; METHADONE; NARCOTICS; SUBSTANCE-RELATED DISORDERS; THERAPEUTIC EQUIVALENCY;

EID: 0031709855     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018936     Document Type: Article

References (26)

1. Sass H: Pro und Contra: Substitution Drogenabhängiger mit Methadon. Nervenarzt 1991; 62:521-523.
2. Scott CC, Robbins EB, Chen KK: Pharmacological comparison of the optical isomers of methadon. J Pharmacol 1948;93:282-286.
3. Isbell H, Eisenman AJ: The addiction liability of some drugs of the methadon series. J Pharmacol Exp Ther 1948;93:305-313.
4. Fraser HF, Isbell H: Human pharmacology and addictiveness of certain dextroisomers of synthetic analgesics: I. d-3-Hydroxy-N-phenethylmorphinan. II. d-3-Methoxy-N-phenethylmorphinan. III. d-Methadone. Bull Narcotics 1962; 14:25-35.
5. Sullivan HR, Due SL, McMahon RE: The difference in activity between (+)-and (-)-methadone is intrinsic and not due to a difference in metabolism. J Pharm Pharmacol 1972;27:728-732.
6. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N: Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1976; 21:147-157.
7. Judson BA, Horns WH, Goldstein A: Side effects of levomethadone and racemic methadone in a maintenance program. Clin Pharmacol Ther 1976;20:445-449.
8. 2, delta, kappa opioid receptor binding profiles of methadone stcreoisomers and morphine. Life Sci 1995;56:PL45-50.
9. Kreek MJ, Hachey DL, Klein PD: Stereoselective disposition of methadone in man. Life Sci 1979;24:925-932.
10. Beck O, Boreus LO, Lafolic P, Jacobsson G: Chiral analysis of methadone in plasma by high performance liquid chromatography. J Chromatogr 1991;570:198-202.
11. Kristensen K, Angelo HR: Stereospecific gas chromatographic method for determination of methadone in scrum. Chiralty 1992;4:263-267.
12. 1-acid glycoprotein. Clin Pharmacol Ther 1990;47:338-346.
13. 1-acid glycoprotein): Determinant of free fraction in plasma. Clin Pharmacol Ther 1981; 29:211-217.
14. Kristensen K, Blemmer T, Angelo HR, Christup LL, Drenck NE, Rasmussen SN, Sjøgren P: Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996;18:221-227.
15. Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P: Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996;50:385-389.
16. 16a Staib AH, Krause JKA, Tursch M, Lang P, Hellenbrecht D: Comparison of the therapeutic outcome of racemic vs. levomethadone in a methadone maintenance therapy program - a double-blind study. Arch Pharmacol 1995;351 (suppl. 1):R17, A67.
17. 16b Staib AH, Fuhr U, Krause JKA, de Vos JW, van Wilgenburg H, Ufkes JGR, Hellenbrecht D: Racemic vd. levomethadone for maintenance in opiate addicts. Thérapie 1995;50 (suppl 1).
18. Csikszentmihaly M, Larson R: Validity and reliability of the experience sampling method. J Nerv Ment Dis 1987;175:526-536.
19. De Vries MW: Investigating mental disorders in their natural settings. J Nerv Ment Dis 1987; 175:509-513.
20. Kaplan CD: Drug craving and drug use in the daily life of heroin addicts; in dc Vrics MW (ed): The Experience of Psychopathology: Investigating Mental Disorders in Their Natural Settings. Cambridge. Cambridge University Press, 1992, pp 193-218.
21. De Vos JW, van Wilgenburg H, van den Brink W, Kaplan CD, de Vries MW: Patterns of craving and pharmacokinetics in longterm opiate addicts in methadone maintenance therapy. Addict Res 1996;3:285-295.
22. Parrino MW: State methadone treatment guidelines. US Department of Health and Human Services, 1993, publication No. (SMA) 93-1991.
23. De Vos JW, Geerlings PJ, van den Brink W, Ufkes JGR, van Wilgenburg H: Pharmacokinetics of methadone and its primary metabolite in twenty opiate addicts. Eur J Clin Pharmacol 1995;48:361-366.
24. 8]methadone. J Pharm Sci 1982;71:40-43.
25. Verebely K, Volavka J, Mulé S, Resnick R: Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975;18:180-190.
26. Nilsson M-I, Änggard E, Holmstrand J, Gunne L-M: Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the induction phase. Eur J Clin Pharmacol 1982;22:343-349.